12 Month Price Forecast For BPMC
Distance to BPMC Price Forecasts
BPMC Price Momentum
๐ค Considering Blueprint Medicines (BPMC)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 11:40 AM UTC
BPMC Analyst Ratings & Price Targets
Based on our analysis of 29 Wall Street analysts, BPMC has a bullish consensus with a median price target of $130.00 (ranging from $83.00 to $169.00). The overall analyst rating is Strong Buy (8.1/10). Currently trading at $93.94, the median forecast implies a 38.4% upside. This outlook is supported by 14 Buy, 5 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BPMC Analyst Consensus
BPMC Price Target Range
Latest BPMC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BPMC.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 14, 2025 | Needham | Ami Fadia | Buy | Reiterates | $133.00 |
Feb 14, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $135.00 |
Feb 14, 2025 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $125.00 |
Feb 13, 2025 | Needham | Ami Fadia | Buy | Reiterates | $133.00 |
Feb 4, 2025 | JP Morgan | Brian Cheng | Overweight | Maintains | $129.00 |
Jan 27, 2025 | Piper Sandler | Christopher Raymond | Neutral | Maintains | $119.00 |
Jan 15, 2025 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $125.00 |
Jan 13, 2025 | Needham | Ami Fadia | Buy | Reiterates | $135.00 |
Jan 13, 2025 | Wedbush | David Nierengarten | Outperform | Reiterates | $124.00 |
Jan 2, 2025 | Stephens & Co. | Overweight | Reiterates | $0.00 | |
Dec 17, 2024 | Needham | Buy | Reiterates | $0.00 | |
Dec 11, 2024 | Guggenheim | Michael Schmidt | Buy | Reiterates | $0.00 |
Dec 9, 2024 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $125.00 |
Nov 18, 2024 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $125.00 |
Nov 15, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $135.00 |
Nov 15, 2024 | Needham | Ami Fadia | Buy | Reiterates | $135.00 |
Nov 14, 2024 | JP Morgan | Brian Cheng | Overweight | Initiates | $126.00 |
Oct 31, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $135.00 |
Oct 31, 2024 | Needham | Ami Fadia | Buy | Maintains | $135.00 |
Oct 31, 2024 | Wells Fargo | Derek Archila | Overweight | Maintains | $151.00 |
Stocks Similar to Blueprint Medicines Corp
The following stocks are similar to Blueprint Medicines based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Blueprint Medicines Corp (BPMC) Financial Data
Blueprint Medicines Corp has a market capitalization of $6.05B with a P/E ratio of -87.8x. The company generates $508.82M in trailing twelve-month revenue with a -13.2% profit margin.
Revenue growth is +103.4% quarter-over-quarter, while maintaining an operating margin of -28.2% and return on equity of -31.3%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Blueprint Medicines Corp (BPMC) Company Overview
About Blueprint Medicines Corp
Develops precision therapies for cancer and blood disorders.
The company focuses on creating targeted medicines for specific genomic alterations in cancers and blood disorders, generating revenue through the sale of these therapies post-approval. It also engages in collaboration and licensing agreements with other pharmaceutical companies to expand its reach and pipeline.
Blueprint Medicines is headquartered in Cambridge, Massachusetts, and has a diverse pipeline that includes treatments for various forms of cancer and blood disorders. The company was previously known as Hoyle Pharmaceuticals, Inc. and has established partnerships with several notable firms in the pharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
638
CEO
Ms. Kathryn Haviland M.B.A.
Country
United States
IPO Year
2015
Website
www.blueprintmedicines.comBlueprint Medicines Corp (BPMC) Latest News & Analysis
Blueprint Medicines Corporation (NASDAQ: BPMC) will hold a live conference call and webcast on February 5, 2025, at 8:00 a.m. for investors and stakeholders.
Blueprint Medicines' upcoming conference call may reveal key updates on financial performance, drug development, or strategic plans, influencing stock price and investment decisions.
Blueprint Medicines (BPMC) is not expected to achieve an earnings beat in its upcoming report due to lacking the necessary key ingredients. Investors should prepare for this outcome.
Blueprint Medicines may report disappointing earnings, potentially leading to a decline in share price and affecting investor confidence. Key expectations could influence trading strategies.
Blueprint Medicines Corporation (BPMC) has reached a key support level and experienced a "golden cross," indicating potential upward momentum in its stock.
The "golden cross" suggests bullish momentum for BPMC, indicating potential price increases, making it an appealing option for traders seeking upward trends.
Peak revenue opportunity for systemic mastocytosis is updated to $4 billion, with AYVAKIT expected to reach $2 billion by 2030. BLU-808 shows promising results in Phase 1 study. CEO to present at J.P. Morgan conference.
Peak revenue potential for systemic mastocytosis is now estimated at $4 billion, driven by strong AYVAKIT sales and new data on BLU-808, signaling growth opportunities for investors.
Blueprint Medicines (BPMC) shares rose significantly with above-average trading volume, though recent earnings estimate revisions may not lead to further price increases soon.
Surging shares and higher trading volume suggest increased investor interest in Blueprint Medicines, but mixed earnings revisions indicate potential volatility ahead.
BPMC stock surged 18% following the company's positive 2025 outlook, highlighting expected growth in Ayvakit sales and advancements in its pipeline.
BPMC's 18% stock rally signals strong market confidence in its growth potential, driven by positive sales forecasts for Ayvakit and advancements in its drug pipeline.
Frequently Asked Questions About BPMC Stock
What is Blueprint Medicines Corp's (BPMC) stock forecast for 2025?
Based on our analysis of 29 Wall Street analysts, Blueprint Medicines Corp (BPMC) has a median price target of $130.00. The highest price target is $169.00 and the lowest is $83.00.
Is BPMC stock a good investment in 2025?
According to current analyst ratings, BPMC has 14 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $93.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for BPMC stock?
Wall Street analysts predict BPMC stock could reach $130.00 in the next 12 months. This represents a 38.4% increase from the current price of $93.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Blueprint Medicines Corp's business model?
The company focuses on creating targeted medicines for specific genomic alterations in cancers and blood disorders, generating revenue through the sale of these therapies post-approval. It also engages in collaboration and licensing agreements with other pharmaceutical companies to expand its reach and pipeline.
What is the highest forecasted price for BPMC Blueprint Medicines Corp?
The highest price target for BPMC is $169.00 from at , which represents a 79.9% increase from the current price of $93.94.
What is the lowest forecasted price for BPMC Blueprint Medicines Corp?
The lowest price target for BPMC is $83.00 from at , which represents a -11.6% decrease from the current price of $93.94.
What is the overall BPMC consensus from analysts for Blueprint Medicines Corp?
The overall analyst consensus for BPMC is bullish. Out of 29 Wall Street analysts, 14 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $130.00.
How accurate are BPMC stock price projections?
Stock price projections, including those for Blueprint Medicines Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.